Proton MR Spectroscopy in Mild Cognitive Impairment and Alzheimer Disease: Comparison of 1.5 and 3 T

References

1. ↵
   Bernstein MA, Huston J III, Lin C, Gibbs GF, Felmlee JP. High resolution intracranial and cervical MRA at 3.0T: technical considerations and initial experience. Magn Reson Med 2001;46:955–962

   CrossRefPubMedWeb of Science
2. ↵
   Hetherington HP, Pan JW, Chu WJ, Mason GF, Newcomer BR. Biological and clinical MRS at ultra-high field. NMR Biomed 1997;10:360–371

   CrossRefPubMedWeb of Science
3. ↵
   Barker PB, Hearshen DO, Boska MD. Single-voxel proton MRS of the human brain at 1.5T and 3T. Magn Reson Med 2001;45:765–769

   CrossRefPubMedWeb of Science
4. Gruetter R, Weisdorf SA, Rajanayagan V, et al. Resolution improvements in in vivo ¹H NMR spectra with increased magnetic field strength. J Magn Reson 1998;135:260–264

   CrossRefPubMed
5. ↵
   Gonen O, Gruber S, Li BSY, Mlynarik V, Moser E. Multivoxel 3D proton spectroscopy in the brain at 1.5 versus 3.0 T: signal-to-noise ratio and resolution comparison. AJNR Am J Neuroradiol 2001;22:1727–1731

   Abstract/FREE Full Text
6. ↵
   Kantarci K, Jack CR, Xu YC, et al. Regional metabolic patterns in mild cognitive impairment and Alzheimer’s diseasez: a ¹H MRS study. Neurology 2000;55:210–217

   Abstract/FREE Full Text
7. ↵
   Catani M, Cherubini A, Howard R. ¹H MR spectroscopy differentiates mild cognitive impairment from normal brain aging. Neuroreport 2001;12:2315–2317

   CrossRefPubMedWeb of Science
8. ↵
   Petersen RC, Smith GE, Waring SC, Ivnik RJ, Tangalos EG, Kokmen E. Mild cognitive impairment: clinical characterization and outcome. Arch Neurol 1999;56:303–308

   CrossRefPubMedWeb of Science
9. ↵
   Petersen RC, Stevens JC, Ganguli M, Tangalos EG, Cummings JL, DeKosky ST. Practice parameter: early detection of dementia—mild cognitive impairment (an evidence-based review). Report of the Quality Standards Subcommittee of the American Academy of Neurology. Neurology 2001;56:1133–1142

   Abstract/FREE Full Text
10. ↵
    Petersen RC, Doody R, Kurz A, et al. Current concepts in mild cognitive impairment. Arch Neurol 2001;58:1985–1992

    CrossRefPubMedWeb of Science
11. ↵
    Hattori N, Abe K, Sakoda S, Sawada T. Proton MR spectroscopic study at 3 Tesla on glutamate/glutamine in Alzheimer’s disease. Neurochemistry 2002;13:183–186
12. ↵
    Petersen RC, Kokmen E, Tangalos E, Ivnik RJ, Kurland LT. Mayo Clinic Alzheimer’s Disease Patient Registry. Aging 1990;2:408–415

    PubMed
13. ↵
    Folstein MF, Folstein SE, McHugh PR. “Mini Mental State ”: a practical method for grading the cognitive state of patients for the clinician. J Psychiatr Res 1075;12:189–198

    CrossRef
14. ↵
    Mattis S. Dementia Rating Scale: Professional Manual. Odessa, FL: Psychological Assessment Resources Inc;1988
15. ↵
    American Psychiatric Association. DSM-III-R. Diagnostic and statistical manual of mental disorders. 3rd ed, revised. Washington, DC: American Psychiatric Association;1987
16. ↵
    Mc Khann GM, Drachman D, Folstein M, Katzman R, Price D, Stadlan EM. Clinical diagnosis of Alzheimer’s disease: report of the NINCDS-ADRDA work group under the auspices of the Department of Health and Human Services Task Force on Alzheimer’s Disease. Neurology 1984;34:939–944

    Abstract/FREE Full Text
17. ↵
    Webb PG, Sailasuta N, Kohler SJ, Raidy T, Moats RA, Hurd RE. Automated single-voxel proton MRS: technical development and multisite verification. Magn Reson Med 1994;31:365–373

    PubMedWeb of Science
18. ↵
    Provencher SW. Estimation of metabolite concentrations from localized in vivo proton NMR spectra. Magn Reson Med 1993;30:672–679

    CrossRefPubMedWeb of Science
19. ↵
    Sokal RR, Rohlf FJ. Biometry. 2nd ed. New York: WH Freeman & Co;1981 :859
20. ↵
    DeLong ER, DeLong EM, Clarke-Pearson DL. Comparing the areas under two or more correlated receiver operating characteristic curves: a nonparametric approach. Biometrics 1988;44:837–845

    CrossRefPubMedWeb of Science
21. ↵
    Chang L, Zhong K, Carasig D, Zimmerman L, Ernst T. Proton MRS in HIV patients at 4 Tesla (abstr). In: Proceedings of the 10th Meeting of the International Society for Magnetic Resonance in Medicine 2002. Berkeley, Calif: International Society for Magnetic Resonance in Medicine,2002;986
22. ↵
    Tkac I, Andersen P, Adriany G, Merkle H, Ugurbil K, Gruetter R. In vivo ¹H NMR spectroscopy of the human brain at 7T. Magn Reson Med 2001;46:451–456

    CrossRefPubMedWeb of Science
23. ↵
    Antuono PG, Jones JL, Wang Y, Li SJ. Decreased glutamate + glutamine in Alzheimer’s disease detected in vivo with ¹H-MRS at 0.5T. Neurology 2001;56:737–742

    Abstract/FREE Full Text
24. ↵
    Braak H, Braak E. Neuropathological staging of Alzheimer’s disease. Acta Neuropathol (Berl) 1991;82:239–259

    CrossRefPubMedWeb of Science
25. ↵
    Minoshima S, Giordani B, Berent S, Frey KA, Foster NL, Kuhl DE. Metabolic reduction in the posterior cingulate cortex in very early Alzheimer’s disease. Ann Neurol 1997;42:85–94

    CrossRefPubMedWeb of Science
26. ↵
    Reiman EM, Caselli RJ, Yun LS, et al. Preclinical evidence of Alzheimer’s disease in persons homozygous for the ε 4 allele for apolipoprotein E. N Engl J Med 1996;334:752–758

    CrossRefPubMedWeb of Science
27. ↵
    Scahill RI, Schott JM, Stevens JM, Rossor MN, Fox NC. Mapping the evolution of regional atrophyin Alzheimer’s disease: unbiased analysis of fluid-registered serial MRI. Proc Natl Acad Sci U S A 2002;99:4703–4707

    Abstract/FREE Full Text